Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S; BARACK-D Investigators; BARACK-D Investigators; Regional coordinating centre teams.
Hobbs FDR, et al.
Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30.
Nat Med. 2024.
PMID: 39349629
Clinical Trial.